In an elderly woman in her late 80s with chronic kidney disease (serum creatinine 2.27 mg/dL) and hypertension uncontrolled at 170–190 mm Hg despite furosemide and valsartan (angiotensin II receptor blocker) 160 mg daily, what is the appropriate next step in management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Optimize Diuretic Therapy and Add a Calcium Channel Blocker

In this elderly woman with CKD (creatinine 2.27 mg/dL, suggesting eGFR ~20-30 mL/min) and uncontrolled hypertension (170-190 mmHg) on furosemide and valsartan 160 mg, the priority is to optimize her loop diuretic regimen and add a long-acting dihydropyridine calcium channel blocker as the third agent.

Immediate Management Steps

1. Optimize Loop Diuretic Therapy

The current furosemide regimen is likely inadequate. Resistant hypertension in CKD patients frequently stems from occult volume expansion 1. With her level of renal impairment (creatinine 2.27), thiazide diuretics are ineffective and loop diuretics are essential 1.

Specific diuretic adjustments:

  • Switch from furosemide to torsemide 10-20 mg once daily 2, 1. Torsemide has superior bioavailability and longer duration of action (12-16 hours vs 6-8 hours for furosemide) 3, 1
  • Alternatively, if continuing furosemide, increase to at least twice-daily dosing (furosemide's short duration requires BID dosing for adequate 24-hour control) 1, 4
  • The FDA label supports furosemide doses up to 600 mg/day in severe edematous states, though careful monitoring is required 4

2. Add a Calcium Channel Blocker

Add amlodipine 5 mg daily, titrating to 10 mg as needed 2, 5. This represents the most evidence-based third agent for this clinical scenario:

  • The combination of ARB + loop diuretic + dihydropyridine CCB is well-established for resistant hypertension 1
  • CCBs are first-line agents for isolated systolic hypertension in elderly patients 6
  • In CKD with hypertension, CCBs combined with RAS inhibitors provide effective BP control 5, 7

3. Continue Valsartan

Maintain valsartan 160 mg daily 7, 5. Despite uncontrolled BP, the ARB provides critical renal protection in CKD and should not be discontinued. The 2021 KDIGO guidelines strongly recommend RAS inhibitors in CKD patients with hypertension 7.

Blood Pressure Target

Target BP <140/90 mmHg given her advanced age (late 80s) 6, 5, 7. The 2013 Canadian guidelines specifically recommend SBP <150 mmHg for patients ≥80 years old 6. More aggressive targets (<130/80 mmHg) are appropriate for younger CKD patients but carry increased risk of hypotension and falls in the very elderly 6, 8.

Monitoring Requirements

Within 2-4 weeks of medication changes, check 7, 4:

  • Serum creatinine and potassium (expect up to 30% creatinine rise with optimized therapy; discontinue ARB only if >30% increase) 7
  • Orthostatic vital signs (critical in elderly patients to assess for symptomatic hypotension) 8
  • Electrolytes including sodium and magnesium (loop diuretics cause hypokalemia and hypomagnesemia) 4

Alternative Considerations

If BP remains uncontrolled after optimizing the above regimen:

  • Consider adding spironolactone 12.5-25 mg daily for resistant hypertension 1, 2, though hyperkalemia risk is substantial with eGFR ~20-30 mL/min
  • Evaluate for secondary causes including renal artery stenosis (though revascularization shows no clear benefit over medical therapy in atherosclerotic disease) 9
  • Assess medication adherence and exclude interfering substances (NSAIDs, decongestants) 1

Critical Pitfalls to Avoid

  • Do not add a thiazide diuretic at this level of renal function (ineffective when eGFR <30 mL/min) 1
  • Do not combine ACE inhibitor with the existing ARB (increases adverse events without benefit) 2, 7
  • Avoid aggressive BP lowering that causes diastolic BP <60 mmHg or symptomatic hypotension in this elderly patient 10, 6
  • Do not use beta-blockers as additional therapy unless she has heart failure or coronary disease (not first-line in elderly with uncomplicated hypertension) 6, 2

References

Related Questions

In a patient with chronic kidney disease who is already receiving isosorbide dinitrate (Isordil), carvedilol (Coreg) at an increased dose, and hydralazine, but whose systolic blood pressure remains in the 180s, what are the next steps for blood pressure control?
In a patient with stage IV chronic kidney disease who is already taking carvedilol (Coreg) 3.125 mg twice daily, isosorbide dinitrate (Isordil) 5 mg three times daily, and hydralazine 100 mg three times daily, and whose blood pressure remains uncontrolled, what additional antihypertensive medications should be considered?
How should hypertension be managed in a 67‑year‑old woman with diabetes, chronic heart failure, stage 3 chronic kidney disease, and tremor who is currently taking metoprolol 50 mg daily and propranolol 60 mg three times daily, presenting with mild headache and elevated blood pressure (148/90 mm Hg)?
What is the appropriate antihypertensive management for a 56-year-old male with uncontrolled hypertension (158/79 mm Hg), asymptomatic, currently on amlodipine 10 mg daily, chronic kidney disease with eGFR 13 mL/min/1.73 m², and diabetes with hemoglobin A1c 7.2%?
What first‑line antihypertensive should be used in a young woman with asthma and chronic kidney disease (eGFR approximately 46 mL/min/1.73 m²), and how should therapy be monitored?
Why does the diaphragm spasm during CO₂ insufflation in abdominal surgery, and how long does the spasm typically last?
How should I evaluate and treat an adult with an elevated thyroid‑stimulating hormone (TSH) level?
In a patient with grade‑2 peripheral edema who took 70 mg lisdexamfetamine (Venvanse) and has a biomedicine background, which ACE inhibitors, beta‑blockers, or aldosterone antagonists are appropriate, and should he self‑manage these medications or seek physician guidance?
What dose of glucagon should be administered during endoscopic retrograde cholangiopancreatography (ERCP) to relax duodenal smooth‑muscle and reduce spasms?
Is it counterproductive to repeatedly clear the throat in chronic throat clearing?
Should I refer this stable adult Malaysian woman with a three‑week dry cough, lymphocytosis, and recent azithromycin therapy for pertussis to the emergency department?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.